论文部分内容阅读
目的检测卵巢癌细胞株及紫杉醇化疗后卵巢癌组织中JAK2,HSP,基因蛋白表达的变化,探讨其与卵巢癌紫杉醇化疗耐药的关系及临床意义。方法选用卵巢癌紫杉醇耐药细胞株SKOV3/TAX及敏感细胞株SKOV3,及58例卵巢癌组织,包括卵巢癌术后及紫杉醇化疗后复发患者19例(化疗组),术前未化疗患者39例(未化疗组)。采用免疫组化二步法,检测卵巢癌组织及细胞中JAK2,HSP基因的蛋白表达。结果 1.光镜下观察SKOV3/TAX细胞株中JAK2、HSP蛋白表达强度均明显高于SKOV3细胞株;组织中化疗组与未化疗组相比JAK2,HSP的蛋白表达累积光密度值均明显增加(分别为:36987.38±16873.42 vs 27756.29±7136.09;34905.64±12361.87 vs 26684.56±12662.24),差异均有统计学意义(P<0.05)。2.各基因蛋白表达在临床分期,分化程度和病理类型中均无显著性差异。3.JAK2、HSP基因蛋白表达两者间呈正相关关系(r=0.330,P=0.011)。结论 JAK2、HSP基因蛋白表达上调可能与卵巢癌紫杉醇化疗耐药有一定相关性。
Objective To investigate the changes of JAK2, HSP and HSPs expression in ovarian cancer cell lines and paclitaxel-treated ovarian cancer tissues and to investigate their relationship with the chemoresistance of paclitaxel in ovarian cancer and its clinical significance. Methods The ovarian cancer cell line SKOV3 / TAX and SKOV3 / SKOV3 cell line were selected, and 58 cases of ovarian cancer including 19 cases of postoperative ovarian cancer recurrence after chemotherapy and paclitaxel recurrence (chemotherapy group), 39 cases of preoperative chemotherapy (Non-chemotherapy group). Immunohistochemical two-step method was used to detect the protein expression of JAK2 and HSP in ovarian cancer tissues and cells. The results showed that the intensity of JAK2 and HSP protein expression in SKOV3 / TAX cell line was significantly higher than that in SKOV3 cell line by light microscopy. Compared with non-chemotherapy group, the cumulative optical density of JAK2 and HSP protein in the chemotherapy group was significantly increased (36987.38 ± 16873.42 vs 27756.29 ± 7136.09; 34905.64 ± 12361.87 vs 26684.56 ± 12662.24, respectively), the differences were statistically significant (P <0.05). The expression of each gene in clinical stage, differentiation and pathological types were not significantly different. There was a positive correlation between JAK2 and HSP (r = 0.330, P = 0.011). Conclusion The up-regulation of JAK2 and HSP gene proteins may be related to the chemoresistance of paclitaxel in ovarian cancer.